UnitedHealth

On October 15, 2025, Davenport & Co LLC disclosed a purchase of 155,551 shares of UnitedHealth Group (UNH) for the period ended Q3 2025, an estimated $47.04 million trade.

What happened

An SEC filing dated October 15, 2025 shows Davenport increased its position in UnitedHealth Group (UNH 0.38%) by 155,551 shares during Q3 2025.

The estimated transaction value, based on the average closing price during the quarter, was approximately $47.04 million.

The post-trade position reached 739,525 shares, with a market value of $255.34 million.

What else to know

Following this buy, UnitedHealth Group accounts for 1.36% of Davenport $18.76 billion in 13F reportable assets

The firm’s top holdings after the filing:

1. Brookfield Corp: $583.81 million (3.13% of AUM)
2. Microsoft: $478.54 million (2.56% of AUM) as of 2025-09-30
3. Amazon: $451.10 million (2.42% of AUM) as of 2025-09-30
4. Markel: $391.43 million (2.1% of AUM) as of 2025-09-30
5. Nvidia: $375.98 million (2.01% of AUM) as of 2025-09-30

As of October 14, 2025, shares of UnitedHealth Group were priced at $359.93, down 40.6% over the prior year and underperforming the S&P 500 by 53 percentage points over the same period.

Company Overview

Company Snapshot

UnitedHealth Group:

• Offers health benefit plans, pharmacy care services, healthcare management, and data analytics solutions through segments including UnitedHealthcare and Optum.
• Generates revenue primarily from insurance premiums, healthcare services, and pharmacy benefit management, leveraging scale and integrated platforms.
• Serves national and public sector employers, government programs (Medicare, Medicaid), individuals, and healthcare providers across the United States.

UnitedHealth Group is a leading diversified healthcare company with a broad national footprint and an integrated business model spanning insurance, pharmacy benefits, and healthcare services. The company maintains a competitive edge through its extensive provider networks, data-driven solutions, and ability to serve a wide range of customer segments.

Foolish take

Davenport & Company continued to add to their UnitedHealth position, which now accounts for 1.4% of the firm’s portfolio and is its 9th-largest position.

What makes Davenport’s purchases over the last two quarters noteworthy is that they are essentially doubling down on the company right after its stock sold off heavily.

Hampered by ballooning medical costs, changes in leadership, reduced guidance, and mounting regulatory pressure, UnitedHealth’s stock dropped 39% from its highs in just the last six months.

While UnitedHealth has become a battleground stock of sorts lately, it received a major lift after Warren Buffett’s Berkshire Hathaway disclosed it took a $1.6 billion stake in the stock in the second quarter of 2025.

That is great company for Davenport to join, as it also adds to its stake in UnitedHealth.

Regardless of the headwinds facing UnitedHealth, the company remains one of the most dominant health insurers in the United States.

Currently trading at just 16 times earnings and 13 times free cash flow, the risk-reward ratio on UnitedHealth Group is very appealing.

Glossary

13F reportable AUM: Assets under management that must be disclosed in quarterly SEC Form 13F filings by institutional investment managers.
Quarterly average price: The average price of a security over a specific quarter, used for estimating transaction values.
Post-trade holdings: The total number of shares or value held in a security after a trade is completed.
Top holdings: The largest investments in a fund or portfolio, ranked by market value.
Pharmacy benefit management: Services that manage prescription drug programs for health plans, employers, and government programs.
Integrated platforms: Systems that combine multiple services or business functions into a unified offering.
Provider networks: Groups of healthcare professionals and facilities contracted to deliver services to insurance plan members.
Medicare: A U.S. federal health insurance program for people aged 65 and older, and certain younger individuals with disabilities.
Medicaid: A joint federal and state program in the U.S. providing health coverage to eligible low-income individuals.
TTM: The 12-month period ending with the most recent quarterly report.

For decades, UnitedHealth Group (UNH -0.40%) could do no wrong. The company raised its dividend by an exceptional 7,266% from 2010 to 2025, while shares rose as much as 1,700% during this run.

But shares have fallen roughly 40% year to date as the company faces a host of problems, from the murder of Brian Thompson, CEO of major business segment UnitedHealthcare, to federal investigations into allegedly fraudulent Medicare billing practices.

Nonetheless, shares surged 12% on Aug. 14 after filings revealed Berkshire Hathaway had bought over 5 million shares.

Berkshire’s move was seen as a major vote of confidence in the stock — and investors joined a stampede to follow Warren Buffett into the trade. Should you?

Image source: Getty Images.

Big growth potential for all segments

UnitedHealth operates through four segments. Its UnitedHealthcare segment provides consumer-oriented health benefit plans and services for employers. Optum Health provides healthcare management and financial services, while Optum Insight offers data analysis tools, consulting, and tech solutions to healthcare providers. Optum Rx is a direct-to-consumer platform offering pharmacy services and 190 million prescriptions per year to U.S. homes.

In its second-quarter report on July 29, the company reported quarterly revenue of $111.6 billion, up roughly 13% from the year-ago period. The trouble is with margins. For UnitedHealthcare, the biggest segment, operating margin fell from 6.2% in Q1 2025 to 2.4% last quarter. Combined, margin for the three Optum segments fell from 6.1% in Q1 2025 to 4.6% in Q2.

These declines are steep enough that, even with revenue on the upswing, earnings fell from $9.1 billion in Q1 2025 to $5.2 billion last quarter.

Rising medical costs are the chief headwind. In the July earnings report, new CEO Stephen Hensley acknowledged that UNH “significantly underestimated the accelerating medical trend,” and medical costs totaled $6.5 billion more than anticipated.

But management is under no such illusions now. They’re taking actions to boost efficiency and cut waste, from stepping up audits of clinical policy and payment integrity tools, to scaling artificial intelligence (AI) efforts to improve provider and patient experiences while driving down costs. Implementation of AI technologies is part of initiatives the company hopes can deliver almost $1 billion in cost reductions. Perhaps most significantly, the company is raising premiums after saying it underpriced Medicare Advantage plans in 2025.

In the meantime, each of these segments could grow significantly in the years ahead. UnitedHealthcare Employer & Individual just rolled out services in its 30th state, while Optum Rx’s growth outlook is 5%-8% annually. Optum Insight is targeting operating margin of 18%-22%, while the 4.7 million patients receiving value-based care from OptumHealth represent only a fraction of the nearly 340 million Americans who could fall under its 100-plus health plans.

It’s not just Berkshire buying

Berkshire Hathaway’s move in UnitedHealth is getting headlines. But billionaire David Tepper also scooped up 2.3 million shares, while Michael Burry of The Big Short fame bought 350,000 call options on the stock in a bet that shares would rise.

In addition, BlackRock, the world’s biggest asset manager, bought over 1 million shares last quarter. Goldman Sachs bought over 1.1 million shares, while Renaissance Technologies (the fabled fund that achieved an average annual return of 66% for decades) bought over 1.35 million.

As for management, Stephen Hensley invested $25 million just days after becoming CEO, while the company’s CFO bought another $5 million worth in shares. All told, the insider buying of UNH stock outweighed insider selling by a nearly 4:1 margin last quarter.

As the investing legend Peter Lynch observed, insiders can sell for many reasons unrelated to a stock. But they buy for only one: They think shares will go up.

Why UnitedHealth is a buy for retail investors, too

Berkshire officials haven’t commented publicly on their rationale for buying UnitedHealthcare, but it’s possible to speculate on their reasons.

Warren Buffett has called cash flow the most important metric in assessing a business’s potential. In a 2000 letter to shareholders, he wrote that dividend yield, the price-to-earnings ratio, book value, and even growth rates “have nothing to do with valuation except to the extent they provide clues to the amount and timing of cash flows into and from the business.”

Positive cash flow shows the company can cover its obligations, return money to shareholders, and potentially pursue growth and expansion. After floundering in 2024, UnitedHealth’s trailing-12-month operating cash flow has rebounded to $29 billion compared to $24.2 billion at the end of last year.

And if price-to-earnings, dividend yield, and growth rates are only background clues to cash flow, these metrics seem to bode well for UnitedHealth, too.

The company’s price-to-earnings ratio of 13.7 is cheap compared to the S&P 500,
with its average P/E ratio of around 26, while revenue growth of 13% year over year further fuels the bull case. Meanwhile, the company’s recent 5.2% dividend increase — its 15th consecutive annual payout hike — brings its yield to 2.8% as I write this, nearly triple the S&P 500 average.

For investors willing to take a long-term approach and be rewarded with rising income in the meantime, UnitedHealth is a buy.

You’re reading a free article with opinions that may differ
from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to
get instant access to our top analyst recommendations, in-depth research, investing resources,
and more. Learn More

In one case, a person suffered permanent brain damage because of a delayed transfer, The Guardian newspaper reported.

UnitedHealth has allegedly secretly paid nursing homes to reduce hospital transfers — the latest accusations in a series of woes facing the health insurance giant.

The alleged action, first reported by The Guardian newspaper on Wednesday, was part of a series of cost-cutting tactics that have saved the company millions, but at times, risked residents’ health, the publication showed, citing an investigation.

The story, which cites thousands of documents and firsthand accounts of more than 20 former employees of the healthcare company and nursing homes, says that the insurance giant sent its own medical teams to nursing homes to push the cost-cutting measures. As a result, patients who urgently needed medical care did not receive it, including one person who now lives with permanent brain damage after a delayed transfer.

The allegations add to the litany of negatives that have hurt UnitedHealth in the last several months, following a massive cyberattack at its Change Healthcare unit, reports of criminal and civil investigations into the company’s practices, including one for Medicare fraud and the abrupt departure of CEO Andrew Witty last week.

UnitedHealth said in response to the story, “The US Department of Justice investigated these allegations, interviewed witnesses, and obtained thousands of documents that demonstrated the significant factual inaccuracies in the allegations.”

The company also said that the DOJ “declined to pursue the matter”.

Wall Street responds 

Shares have stumbled all year, losing more than 39 percent compared with a 0.6 percent decrease for the Dow. As of noon ET (16:00 GMT), the stock is down more than 3.6 percent.

“The news is only seemingly getting worse for UnitedHealth,” said Sahak Manuelian, managing director, global equity trading at Wedbush Securities.

HSBC downgraded the stock to “reduce” from “hold,” and cut the price target to a street-low of $270.

The brokerage said higher medical costs, pressure on drug pricing and its pharmacy benefit management unit, OptumRx, and a potential Medicaid funding cut can upset the company’s recovery journey.

The United States Department of Justice (DOJ) is carrying out a criminal investigation into UnitedHealth Group for possible Medicare fraud.

The Wall Street Journal (WSJ) first broke the story on Wednesday.

UnitedHealth said it had not been notified by the DOJ about the “supposed criminal investigation reported”, and the company stood by “the integrity of our Medicare Advantage program”.

The DOJ’s healthcare-fraud unit is overseeing the criminal investigation, which focuses on the company’s Medicare Advantage business practices, WSJ reported, citing people familiar with the matter.

While the exact nature of the potential criminal allegations against UnitedHealth is unclear, it has been an active probe since at least last summer, the newspaper said.

A DOJ spokesperson declined to comment to the WSJ about the fresh criminal probe. The department did not immediately respond to requests for comments from the Reuters news agency.

Last week, UnitedHealth said in a regular filing that it had been “involved or is currently involved in various governmental investigations, audits and reviews”, without disclosing further details.

The new investigation follows broader scrutiny into the Medicare Advantage programme, in which Medicare-approved plans from a private company supplement regular Medicare for Americans age 65 and older by covering more services that the government-only plans do not, such as dental and vision services.

In February, the WSJ reported a civil fraud investigation into UnitedHealth’s Medicare practices. The company had then said that it was unaware of any new probe.

In the same month, US Senator Chuck Grassley of Iowa launched an inquiry into UnitedHealth’s Medicare billing practices, requesting detailed records of the company’s compliance programme and other related documents.

The DOJ earlier this month filed a lawsuit accusing three of the largest US health insurers of paying hundreds of millions of dollars in kickbacks to brokers in exchange for steering patients into the insurers’ Medicare Advantage plans.

Nearly half of the 65 million people covered by Medicare, the US programme for people aged 65 and older or with disabilities, are enrolled in Medicare Advantage plans run by private insurers.

The insurers are paid a set rate for each patient, but can be paid more if patients have multiple health conditions. Standard Medicare coverage is managed by the government.

Brewing turmoil

The health insurer has been under pressure for months. On Tuesday, UnitedHealth Group’s CEO, Andrew Witty, stepped down unexpectedly, and the company simultaneously suspended its 2025 financial forecast due to rising medical costs, triggering an 18 percent drop in shares to a four-year low.

Stephen Hemsley, who led the company for more than a decade until 2017, is taking back the reins following setbacks including the December murder of Brian Thompson, the CEO of its insurance unit, which catapulted UnitedHealth into the public consciousness.

On Thursday, after the news of the probe broke, UnitedHealth Group shares plunged 18 percent to hit a five-year low.

“The stock is already in the doghouse with investors, and additional uncertainty will only pile on,” James Harlow, senior vice president at Novare Capital Management, which owns shares in UnitedHealth, told the news agency Reuters.

If losses hold, UnitedHealth will be the worst-performing stock on the S&P 500 index in two of the last three days.

The past month’s selloff has wiped out nearly $300bn from UnitedHealth’s market capitalization, or more than half of its value since its shares hit a record high in November.

May 13 (UPI) — UnitedHealth Group announced Tuesday CEO Andrew Witty will step down, citing “personal reasons.”

Witty will leave the role of CEO and be replaced by Stephen J. Hemsley, effective immediately.

“Leading the people of UnitedHealth Group has been a tremendous honor as they work every day to improve the health system and they will continue to inspire me,” Witty said in a statement without providing further details on his decision to step away from the role.

Witty will continue to serve as a senior adviser to Hemsley, who served as CEO of UnitedHealth Group from 2006 to 2017 and will also remain chair of the board, the company said.

“Steve Hemsley brings a combination of strategic vision and deep operational focus that are highly valuable to our company,” UnitedHealth Group lead independent director Michele Hooper said.

Hemsley first joined UnitedHealth Group as CEO in 1997 and then became president in 1999, before being named board chairperson in 2017.

“We are grateful for Andrew’s stewardship of UnitedHealth Group, especially during some of the most challenging times any company has ever faced,” Hemsley said. “The board and I have greatly valued his leadership and compassion as chief executive and as a director and wish him and his family the best.”

UnitedHealthcare, a subsidiary of UnitedHealth Group, named Tim Noel the CEO of its in January after its former CEO Brian Thompson was shot and killed in Manhattan in December 2024. Police arrested Maryland resident Luigi Mangione for allegedly having gunned down Thompson, to which Mangione has since pleaded not guilty and awaits his next hearing in December.

The company reports it has suspended its outlook for 2025 due in part to the higher-than-expected medical costs of several Medicare Advantage beneficiaries, and also because of a rise in care activity that has been widened to include more in the way of benefit offerings than found in the first quarter.

A class action lawsuit was filed against UnitedHealth Group last week “on behalf of persons or entities who purchased publicly traded UnitedHealth securities between December 3, 2024 and April 16, 2025,” which alleges the company violated the Securities Exchange Act of 1934 in regard to its announced 2024 outlook, which the suit purports to have contained false fiscal guidance.

As of 10:18 a.m., UnitedHealth Group stock has dropped 12.97% in price since the opening bell.